WHO Solidarity Plus
Phase 3
Recruiting
- Conditions
- covid-19.covid-19U07.1
- Registration Number
- IRCT20211221053470N1
- Lead Sponsor
- World Health Organization
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
Hospitalized patients with laboratory-confirmed COVID-19
Adults (age =18 years(
Not expected to be transferred within 72 hours
Exclusion Criteria
In the view of their doctors, no contraindication to use relevant drugs
No evidence of pregnancy or hepatic disease in imatinib group
No evidence of heart failure, TB or liver disease in Infliximab group
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method In-hospital death from any causes. Timepoint: At the end of study. Method of measurement: Physician report.
- Secondary Outcome Measures
Name Time Method In-hospital mortality subdivided by initial respiratory support. Timepoint: At the end of study. Method of measurement: Physician report.;Initiation of ventilation (time to first ventilation) in lower-risk patients. Timepoint: During study. Method of measurement: Physician report.;Duration of hospital stay in lower-risk patients and in higher-risk patients. Timepoint: At the end of study. Method of measurement: Physician report.;SAEs (serious adverse events) or SUSARs (suspected unexpected serious adverse reaction) possibly related to treatment. Timepoint: During study. Method of measurement: Physician report.